Teresa Lamantia is currently Sr. Vice President, Head of US Early Clinical Development (ECD) at QuintilesIMS, Inc. QuintilesIMS is the world’s largest Contract Research Organization (CRO) with 50,000 employees in over 100 country locations. In this role she oversees the operations of the Overland Park, Kansas, Phase I unit and leads the global Clinical Pharmacology and Project Management teams for Early Clinical Development. QuintilesIMS is the CRO industry leader in Phase I Services, named by ISR for the last 4 years. Teresa leads a dedicated team of physicians, clinical pharmacologists, nurses, technicians, project managers, and laboratory personnel to execute on QuintilesIMS ECD Strategies. She has responsibility for profitability, budget, driving sales and marketing, as well as overseeing operations and customer management.

Prior to this role, Teresa held the position of Sr. Vice President, Global Head of Knowledge Management, serving a Clinical Development organization of 22,000 clinical research professionals. Knowledge management provides data and analytics, integrated processes and technology solutions, strategic initiative project management, process re-engineering, productivity, quality and resourcing centers of excellence and change management programs and she was part of the executive team that serves the clinical development organization.
She joined QuintilesIMS in 2002 holding several progressive leadership and management positions across global operations.

Prior to joining QuintilesIMS, Teresa spent 22 years in healthcare and pharmaceutical research roles. She is a registered nurse who has expertise in pediatric critical care and obstetrics and held several other leadership roles. She has provided consultation in management effectiveness and empowerment models nationally. She holds a BSN from Vanderbilt University and an MSN from the University of Cincinnati.